FDA-CVM Establish INAD File for CannEpil Veterinary Program
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Argent Biopharma Ltd has announced that the U.S. FDA Center for Veterinary Medicine has established an Investigational New Animal Drug file for CannEpil, marking a significant regulatory milestone for its veterinary development program. The initial focus of this program is on managing cancer-related pain in companion animals, starting with canine oncology. The establishment of the INAD file allows for formal interactions with the FDA regarding product development and regulatory submissions. Roby Zomer, Chairman, emphasized that this milestone reflects progress in their licensing strategy and the potential for additional value from CannEpil.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Argent Biopharma
- US Veterinary Development Programme for CannEpil Commences
- CannEpil Global Licence Expands into Veterinary Healthcare
- RGT Executes Global CannEpil Licensing Deal for US$5.5M
- Half Yearly Report and Accounts
- Provisional Patent Lodged with USPTO for NanoBodies Platform
Later from Argent Biopharma
- Appendix 4E and 2026 Annual Report
- Argent Signs NLC Licence to Expand Antiviral Portfolio
- Execution of Loan Facility Agreement
- Quarterly Activities/Appendix 4C Cash Flow Report
- RGT Executes Global Licence for Non-Core Cannabis Genetics
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma